Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Rocketing Higher Today

By George Budwell - Feb 25, 2020 at 11:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna wins a key first-mover advantage in the battle against the COVID-19 threat.

What happened

Mid-cap biotech Moderna (MRNA -3.21%) is on the move again today. Shares are up by a noteworthy 11.7% as of 10:23 a.m. EST Tuesday. 

Moderna's shares are jumping in response to news that the company's experimental mRNA COVID-19 vaccine, mRNA-1273, has been shipped to U.S. governmental researchers at the National Institute of Allergy and Infectious Diseases. The company expects the vaccine's first clinical trial to kick off in April. The initial results from this early-stage trial should be available by August. 

Blue background with the word "coronavirus" written on it, with two spiked balls representing the virus next to the word.

Image source: Getty Images.

So what

Inovio Pharmaceuticals, Novavax, and several other biopharmas are also developing vaccines against COVID-19, the illness caused by the new coronavirus. But Moderna beat them all to the punch with its novel vaccine platform. The big question now is whether this experimental vaccine will ever become a moneymaker for the company.

It's very possible that the COVID-19 threat will simply evaporate before any of these early-stage vaccines come to market. That being said, there is a growing chance that COVID-19 might become a regular seasonal illness similar to the common cold or the flu. The virus, after all, has now spread to dozens of countries across the globe. 

Now what

Should investors buy this biotech stock on the COVID-19 vaccine news? The short answer is probably not. It typically takes several years to trial an experimental vaccine -- a process that mRNA-1273 is only now beginning in earnest. So by the time this vaccine is ready for its commercial debut, there's no telling whether COVID-19 will even be a major global health concern. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$137.71 (-3.21%) $-4.57
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.84 (-7.54%) $0.15
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$52.11 (0.31%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.